The Prevalence of Intrinsic Subtypes and Prognosis in Breast Cancer Patients of Different Races
Overview
Oncology
Authors
Affiliations
A recent report indicated that a high prevalence of basal-like breast tumors (estrogen receptor [ER]-negative, progesterone receptor [PR]-negative, human epidermal growth factor receptor [HER] 2-negative, and cytokeratin 5/6-positive and/or HER1-positive) could contribute to a poor prognosis in African American women with breast cancer. It has been reported that Japanese women with breast cancer have a significantly better survival rate than other races in the USA. These findings suggest that breast cancers in Japanese women have favorable biological characteristics. To clarify this hypothesis, we conducted a cohort study to investigate the prevalence of intrinsic subtypes and prognosis for each subtype in 793 Japanese patients. This study revealed a very low prevalence (only 8%) of basal-like breast tumors with aggressive biological characteristics in Japanese patients. Survival analysis showed a significantly poorer prognosis in patients with basal-like tumors than in those with luminal A tumors (ER- and/or PR-positive, and HER2-negative) with favorable biological characteristics. These findings support the hypothesis that breast cancers in Japanese women have more favorable biological characteristics and a better prognosis than those in other races. In conclusion, the prevalence of basal-like breast tumors could influence the prognosis of breast cancer patients of different races. The prevalence of intrinsic subtypes should be taken into account when analyzing survival data in a multi-racial/international clinical study.
Molecular subtypes predict the prognosis of male breast cancer: a retrospective cohort study.
Wang M, Liu D, Zhang Z, Dai X, Chen G, Zhu L Transl Breast Cancer Res. 2024; 4:4.
PMID: 38751485 PMC: 11093005. DOI: 10.21037/tbcr-22-24.
Suzuki K, Ohe R, Kabasawa T, Kitaoka T, Kawai M, Motoi F Breast Cancer. 2023; 30(6):1094-1104.
PMID: 37792212 PMC: 10587303. DOI: 10.1007/s12282-023-01507-9.
Alsughayer A, Dabbagh T, Abdel-Razeq R, Al-Jussani G, Alhassoon S, Sughayer M JCO Glob Oncol. 2022; 8:e2100359.
PMID: 35436143 PMC: 9302262. DOI: 10.1200/GO.21.00359.
Baranska A, Blaszczuk A, Kanadys W, Malm M, Drop K, Polz-Dacewicz M Cancers (Basel). 2021; 13(22).
PMID: 34830807 PMC: 8616467. DOI: 10.3390/cancers13225654.
Chen X, Gao Y, Zhang G, Li B, Ma T, Ma Y J Cancer. 2021; 12(9):2643-2653.
PMID: 33854624 PMC: 8040714. DOI: 10.7150/jca.53303.